126 Notes to the financial statements 21 Other investments 2009 2008 m m At 1st January 478 517 Exchange adjustments 48 129 Additions 175 87 Net fair value movements 57 94 Impairment losses 95 65 Transfer to investments in associates and joint ventures 56 39 Disposals 57 57 At 31st December 454 478 Other investments comprise non-current equity investments which are available-for-sale investments recorded at fair value at each balance sheet date.
For investments traded in an active market, the fair value is determined by reference to the relevant stock exchange quoted bid price.
For other investments, the fair value is estimated by reference to the current market value of similar instruments or by reference to the discounted cash flows of the underlying net assets.
The Group holds a number of equity investments in entities where the Group has entered into research collaborations.
Other investments include listed investments of 245 million 2008 319 million.
On disposal of investments, fair value movements are reclassified from reserves to the income statement based on average cost for shares acquired at different times.
The impairment losses recorded in the tables above have been recognised in the income statement for the year within other operating income, together with amounts reclassified from the fair value reserve on recognition of the impairments.
These impairments initially result from prolonged or significant declines in the fair value of the equity investments below acquisition cost, subsequent to which any further declines in fair value are immediately taken to the income statement.
At 31st December 2009 impaired assets with a fair value of 105 million 2008 118 million are included in other investments.
The transfer to associates relates to the Groups holding in Aspen Pharmacare Holdings Limited, which increased during the year to 19%.
22 Other non-current assets 2009 2008 m m Amounts recoverable under insurance contracts 299 293 Pension schemes in surplus 23 39 Other receivables 261 247 583 579 23 Inventories 2009 2008 m m Raw materials and consumables 1,153 1,127 Work in progress 1,437 1,295 Finished goods 1,474 1,634 4,064 4,056 GSK Annual Report 2009 Financial statements P91P182
